Analysts project the GLP-1 obesity and diabetes market will reach somewhere between $100 billion and $200 billion by 2030, depending on pricing dynamics and oral formulation uptake. Eli Lilly and Novo Nordisk are generating tens of billions in annual revenue from tirzepatide and semaglutide. Behind them, a crowded pipeline of next-generation incretins is racing toward approval.
Roche entered this race in 2024 when it acquired Carmot Therapeutics for $2.7 billion, gaining CT-388 (RO7690479), a dual GLP-1R/GIPR agonist with a distinct receptor profile. In January 2026, Roche announced Phase II results showing 22.5% placebo-adjusted weight loss at 48 weeks, with no plateau in sight. Phase III trials (Enith1 and Enith2) are now underway.
For pharma strategists, BD teams, and investors, the core question is straightforward: where does CT-388 actually fit in this increasingly competitive landscape? Answering that question properly requires integrating clinical trial data, receptor pharmacology, post-marketing safety surveillance, genetic evidence, and patent analysis into a single coherent picture.
We ran that analysis as a single K-Dense Web session. Here is what came back.
K-Dense Web generated a complete competitive intelligence package for CT-388, covering pipeline mapping, receptor pharmacology, clinical efficacy, FAERS safety analysis, SWOT synthesis, and Phase III trial design recommendations.
What K-Dense Web built
From a single prompt, K-Dense Web designed and executed a 7-step analytical pipeline, writing and running each Python script autonomously. The platform queried four live external databases, generated five publication-quality figures, compiled a 44-page LaTeX PDF report with 30+ verified citations, and ran an automated peer review on its own output.
| Step | Analysis | Data Source | Output |
|---|---|---|---|
| 1 | Pipeline aggregation | ClinicalTrials.gov API v2 | 8-drug competitive pipeline map |
| 2 | Receptor pharmacology | ChEMBL API + curated literature | EC50 binding data for 8 molecules |
| 3 | Genetic evidence | Open Targets GraphQL API v4 | GLP1R/GIPR disease associations |
| 4 | Safety surveillance | openFDA FAERS API (2020-2026) | PRR disproportionality analysis |
| 5 | Clinical efficacy | Published trial data (STEP, SURMOUNT) | Standardized cross-drug comparison |
| 6 | Visualization | All upstream data | 5 publication-quality figures |
| 7 | Strategic synthesis | All upstream analysis | SWOT + Phase III recommendations |
Total outputs: 8 structured data files (CSV, JSON), 5 figures, 7 reproducible Python scripts, a 44-page compiled PDF, and a peer review document with 7 major and 8 minor comments.
The competitive pipeline: 8 drugs, 4 mechanisms
K-Dense Web queried ClinicalTrials.gov API v2 and mapped the entire incretin agonist pipeline by development phase, mechanism class, and administration route.
Figure 1: GLP-1/incretin competitive pipeline. Bubble size reflects registered trial count. Tirzepatide and semaglutide (50 trials each) dominate the approved space. CT-388 (5 trials) is entering Phase 3.
| Drug | Mechanism | Phase | Route | Active Trials |
|---|---|---|---|---|
| Tirzepatide | Dual GLP-1R/GIPR | Approved | Injectable | 50 |
| Semaglutide | GLP-1R mono | Approved | Both (oral + injectable) | 50 |
| Retatrutide | Triple GLP-1R/GIPR/GCGR | Phase 3 | Injectable | 33 |
| Orforglipron | GLP-1R mono | Phase 3 | Oral | 46 |
| Survodutide | Dual GLP-1R/GCGR | Phase 3 | Injectable | 24 |
| CT-388 | Dual GLP-1R/GIPR | Phase 3 | Injectable | 5 |
| Pemvidutide | Dual GLP-1R/GCGR | Phase 2 | Injectable | 7 |
| Amycretin | Dual GLP-1R/Amylin | Phase 1 | Both | 1 |
The Phase 3 tier is crowded. Four drugs are competing for market entry alongside the two approved leaders. CT-388 needs a clear differentiation story. The analysis found one in its receptor pharmacology.
Receptor pharmacology: the 1:1 balanced agonist
This is the central finding. CT-388 is the only dual GLP-1R/GIPR agonist in development with near-perfect balanced potency at both receptors.
K-Dense Web compiled EC50 binding data from ChEMBL and curated literature sources (Coskun et al. 2022 for tirzepatide, Urva et al. 2022 for retatrutide, Carmona et al. EASD 2023 for CT-388) and plotted them on a log-scale scatter.
Figure 2: Receptor selectivity scatter. CT-388 (red) sits on the 1:1 diagonal, indicating balanced engagement of both GLP-1R and GIPR (EC50 = 0.030 nM for both). Tirzepatide (blue) sits below the line, reflecting its 9:1 GIPR-biased profile. Drugs without GIPR activity (semaglutide, orforglipron, survodutide, pemvidutide) are plotted along the bottom axis.
| Drug | GLP-1R EC50 (nM) | GIPR EC50 (nM) | GIPR/GLP-1R Ratio | Profile |
|---|---|---|---|---|
| CT-388 | 0.030 | 0.030 | 1.00 | Balanced |
| Tirzepatide | 0.054 | 0.006 | 0.11 | 9:1 GIPR-biased |
| Retatrutide | 0.028 | 0.008 | 0.29 | GIPR-biased + GCGR |
| Semaglutide | 0.032 | N/A | N/A | GLP-1R selective |
| Orforglipron | 4.30 | N/A | N/A | GLP-1R selective (small molecule) |
The 1:1 ratio matters because both receptors have strong genetic validation for obesity. K-Dense Web queried the Open Targets Platform API and found that GLP1R carries an obesity association score of 0.72 and GIPR scores 0.69. A well-studied GIPR missense variant, E354Q (rs1800437), is associated with reduced BMI in large-scale GWAS and Mendelian randomization analyses. This variant alters GIPR signaling kinetics, providing genetic evidence that GIPR modulation meaningfully impacts adiposity.
Tirzepatide's 9:1 GIPR bias means it preferentially activates the GIP receptor while engaging GLP-1R at a lower relative potency. CT-388's balanced profile represents a genuinely different pharmacological hypothesis: that equimolar engagement of both receptors may yield a distinct efficacy and tolerability profile.
A caveat flagged by the automated peer review: all EC50 values are from heterogeneous published assays using different cell lines and reporter constructs. Apparent differences smaller than 2-fold may not be biologically meaningful. A unified head-to-head pharmacology comparison in a standardized assay system would be needed to confirm these rankings.
Clinical efficacy: where CT-388 stands
K-Dense Web curated placebo-controlled weight loss data from peer-reviewed publications (STEP 1-4, SURMOUNT-1-4, retatrutide Phase 2, CT-388 Phase 2) and applied a critical methodological filter: only Standard-design, Non-T2D trials were used for cross-drug comparisons. This eliminates confounding from intensive lifestyle enrichment (STEP 3, SURMOUNT-3) and run-in/maintenance designs (STEP 4, SURMOUNT-4) that inflate active-arm weight loss estimates.
Figure 3: Head-to-head efficacy comparison restricted to Standard-design, Non-T2D trials. CT-388's 16.9% is from a 24-week interim analysis; all other drugs are at trial endpoint (48-72 weeks). The red caveat box warns against direct comparison.
The session used the earliest available published data for CT-388 (24-week interim from ADA/ENDO 2024) and projected a 48-week plateau of 24 to 26% based on trajectory extrapolation from tirzepatide's weight-loss kinetics. That projection was subsequently tested against real-world data.
Updated result (January 26, 2026): Roche announced full 48-week Phase II results from the CT388-103 trial (NCT06525935, n=469). At the highest dose (24 mg), CT-388 achieved 22.5% placebo-adjusted weight loss (efficacy estimand) without reaching a weight loss plateau. Using the treatment-regimen estimand, the placebo-adjusted weight loss was 18.3%. At week 48, 47.8% of participants on the 24 mg dose had lost 20% or more of their body weight, and 26.1% had lost 30% or more.
| Drug | Trial | PBO-adj Weight Loss | Duration | Status |
|---|---|---|---|---|
| Retatrutide | Phase 2 (12 mg) | 22.1% | 48 wk | Phase 3 (TRIUMPH) |
| CT-388 | Phase 2 (24 mg) | 22.5% | 48 wk | Phase 3 (Enith) |
| Tirzepatide | SURMOUNT-1 (15 mg) | 17.8% | 72 wk | Approved |
| Semaglutide | STEP 1 (2.4 mg) | 12.5% | 68 wk | Approved |
The updated CT-388 data puts it essentially neck-and-neck with retatrutide at the 48-week mark, and ahead of tirzepatide's 72-week result. Notably, CT-388's weight loss curve had not plateaued at 48 weeks, suggesting the final treatment effect could be even higher at 72 weeks in the Phase III program.
FAERS safety surveillance: dual agonists vs. mono agonists
CT-388 has no post-marketing safety data (it is not yet approved). To characterize the class-level safety profile, K-Dense Web performed a Proportional Reporting Ratio (PRR) disproportionality analysis using the openFDA FAERS API, comparing semaglutide and tirzepatide across six safety signals from 2020 through April 2026. The detection threshold followed the Evans et al. standard: PRR >= 2.0, chi-squared >= 4.0, and n >= 3.
| Drug | Signal | n | PRR | 95% CI | Detected? |
|---|---|---|---|---|---|
| Semaglutide | Pancreatitis | 1,733 | 8.61 | 8.21-9.04 | YES |
| Tirzepatide | Pancreatitis | 1,410 | 3.93 | 3.73-4.15 | YES |
| Semaglutide | Thyroid neoplasm | 203 | 2.48 | 2.16-2.85 | YES |
| Tirzepatide | Thyroid neoplasm | 144 | 0.99 | 0.84-1.17 | NO |
| Semaglutide | Suicidal ideation | 576 | 2.47 | 2.28-2.68 | YES |
| Tirzepatide | Suicidal ideation | 340 | 0.82 | 0.74-0.92 | NO |
| Semaglutide | Bowel obstruction | 1,176 | 7.47 | 7.05-7.92 | YES |
| Tirzepatide | Bowel obstruction | 591 | 2.07 | 1.91-2.25 | YES |
| Semaglutide | Gastroparesis | 6 | 9.41 | 4.10-21.6 | YES |
| Tirzepatide | Gastroparesis | 5 | 4.40 | 1.78-10.9 | YES |
| Semaglutide | Aspiration | 115 | 1.03 | 0.86-1.24 | NO |
| Tirzepatide | Aspiration | 56 | 0.28 | 0.22-0.37 | NO |
Score: Semaglutide 5/6 signals. Tirzepatide 3/6 signals.
Tirzepatide's pancreatitis PRR (3.93) is 2.2x lower than semaglutide's (8.61). The thyroid neoplasm and suicidal ideation signals that are detected for semaglutide do not reach the disproportionality threshold for tirzepatide.
Figure 4: Quarterly FAERS reporting rates, normalized by total drug-specific reports. Left panel: GI adverse events (nausea, vomiting, diarrhea, abdominal pain). Right panel: pancreatitis. Tirzepatide's early spikes reflect the Weber effect (elevated reporting in the first 1-2 years post-approval). Both drugs converge to similar GI rates by 2024, but semaglutide maintains a persistently higher pancreatitis rate.
The automated peer review flagged two important caveats. First, tirzepatide's lower PRR may partly reflect its shorter post-approval period and the Weber effect rather than a genuine mechanistic difference. Second, the gastroparesis PRR comparison (9.41 vs 4.40) is based on extremely small event counts (n=6 and n=5), making the confidence intervals wide and the comparison statistically fragile.
For CT-388, these findings offer an inference but not a guarantee. Both CT-388 and tirzepatide are dual GLP-1R/GIPR agonists, but they differ in peptide scaffold, fatty acid modification, half-life, and receptor signaling bias. Phase 3 safety data will be necessary to confirm whether CT-388 inherits tirzepatide's favorable safety differential.
Strategic synthesis: SWOT and competitive positioning
K-Dense Web synthesized all upstream data into a quantitatively grounded SWOT analysis. Every element is anchored to specific numbers from the analysis.
Strengths
- S1: Balanced receptor pharmacology. The only GLP-1R/GIPR dual agonist with a 1:1 potency ratio. Genetically supported by GIPR E354Q variant association with BMI and Open Targets obesity score of 0.69.
- S2: Competitive efficacy trajectory. 22.5% PBO-adjusted weight loss at 48 weeks, comparable to retatrutide and ahead of tirzepatide's SURMOUNT-1. No plateau at 48 weeks.
- S3: Differentiated safety inference. Structural analogy to tirzepatide suggests fewer class-effect signals than semaglutide (3/6 vs 5/6 FAERS signals; pancreatitis PRR 2.2x lower).
- S4: Strong IP position. Compound patents extend to approximately 2041 (US), five years beyond tirzepatide (2036).
- S5: Phase 3 ready. Five registered trials, Phase 3 program (Enith1, Enith2) underway.
Weaknesses
- W1: Late mover. Tirzepatide has a 4-5 year head start in market penetration and prescriber habit formation.
- W2: No post-marketing safety database. Class-effect risks remain unquantified for CT-388 specifically (0 FAERS reports vs 120,881 for tirzepatide).
- W3: Oral competitor threat. Orforglipron (46 trials, 23 in Phase 3) may capture patients who prefer oral over injectable therapy.
Opportunities
- O1: Post-tirzepatide patent cliff. CT-388 would be the only branded dual GLP-1R/GIPR agonist with full exclusivity after tirzepatide faces generic competition in the 2036 to 2041 window.
- O2: Cardiovascular outcome expansion. GLP1R carries an Open Targets CVD association score of 0.35. A dedicated CVOT could unlock a CV risk reduction label, the premium indication in this class.
- O3: MASH/NASH indication. Tirzepatide achieved MASH resolution rates of 44% to 62% across doses in the SYNERGY-NASH trial (up to 73% on the efficacy estimand at 15 mg). CT-388's balanced GIP/GLP-1 engagement provides a mechanistic rationale for pursuing this high-value indication.
Threats
- T1: Retatrutide's triple-agonist efficacy. The GLP-1R/GIPR/GCGR triple agonist showed 22.1% weight loss at 48 weeks in Phase 2 and may set a higher efficacy ceiling in Phase 3 (TRIUMPH trials).
- T2: Payer resistance. Without head-to-head superiority data against tirzepatide, CT-388 could face step-edit restrictions requiring tirzepatide failure first.
Figure 5: Patent exclusivity timelines. Semaglutide's US compound patents expire around 2031. Tirzepatide extends to 2036. CT-388's compound patents run to approximately 2040-2041 (US), creating a five-year exclusivity window as the sole branded dual GLP-1R/GIPR agonist after tirzepatide faces generic entry.
The strategic differentiation thesis that emerged from the analysis: CT-388 is best positioned as the "Balanced Precision Dual Agonist," differentiated from tirzepatide by equimolar GIP:GLP-1 engagement (1:1 vs 9:1), a distinct peptide scaffold with independent IP, and a five-year extended exclusivity window. The optimal Phase III strategy is to demonstrate non-inferiority to tirzepatide at 72 weeks, then pursue superiority via a CVOT and/or MASH indication to unlock premium formulary access.
The deliverable: a 44-page competitive intelligence report
The session did not stop at data analysis. K-Dense Web's writing agent compiled all findings into a publication-quality LaTeX document:
- 44 pages with professional pharmaceutical formatting
- 6 embedded figures (graphical abstract, pipeline, pharmacology, efficacy, FAERS, patents)
- 30+ verified citations from NEJM, Lancet, JAMA, and other top-tier journals
- Full SWOT analysis with quantitative anchoring for every element
- Phase III trial design recommendations (a four-trial program covering obesity, T2D, CVOT, and MASH)
- Automated peer review with 7 major and 8 minor comments, resulting in an "Accept with Minor Revisions" recommendation
The peer review itself is a notable feature. It identified legitimate methodological concerns (assay heterogeneity in the pharmacology comparison, Weber effect as a confounder in the FAERS analysis, uncertainty bounds on the efficacy extrapolation) and recommended specific textual revisions. This kind of structured self-critique is unusual for automated analysis and adds a layer of quality assurance to the final deliverable.
Download the Full PDF Report (44 pages)
Explore the Complete Session Data
What this means for pharma teams
Building a competitive intelligence package of this depth on a development-stage obesity drug typically requires a team of analysts spending two to four weeks. They would need to query ClinicalTrials.gov, pull pharmacology data from ChEMBL, run FAERS disproportionality analyses, compile and standardize clinical efficacy data across trial designs, build patent landscape timelines, and synthesize everything into a strategic framework with actionable recommendations.
K-Dense Web compresses that into a single autonomous session. The platform:
- Queries real data sources. ClinicalTrials.gov, ChEMBL, Open Targets, openFDA FAERS. No LLM hallucinations.
- Applies rigorous methodology. Standard Non-T2D trial filtering for efficacy comparisons. PRR disproportionality analysis with established signal detection criteria. Quantitatively grounded SWOT.
- Produces IC-ready deliverables. Publication-quality figures, LaTeX-typeset PDF, structured data files, and automated peer review.
- Documents everything. Every Python script, every API call, every data source is preserved for reproducibility and audit.
Whether you are evaluating a licensing opportunity, preparing a portfolio review, or building conviction on a competitive position, K-Dense Web cuts the timeline from weeks to hours.
Have questions about using K-Dense Web for pharma competitive intelligence? Join our Slack community or reach out at contact@k-dense.ai.
Disclaimer: This analysis was generated by an AI system using publicly available data sources. It is provided for informational and demonstration purposes only and does not constitute financial, investment, or medical advice. Clinical data cited should be verified against primary sources before use in any decision-making context.